Skip to content

Study · Not a test of the peptide alone · 2020

1 result

Anti-obesity drug therapy in clinical practice: Evidence of a poor prescriptive attitude.

Squadrito F, Rottura M, Irrera N, Minutoli L, Bitto A, Barbieri MA, Cicala G, Mecchio A, Pallio G, Marino S, Picciolo G, Altavilla D, Arcoraci V

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2 Jun 2020Cited by 19 (Europe PMC)

PMID32502842 (opens in a new tab)DOI10.1016/j.biopha.2020.110320 (opens in a new tab)PepBankPUB-32502842
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneObservational studyOther

    In a general practice cohort of patients with obesity, liraglutide was prescribed in only 7 patients, because of concomitant diabetes.

    In plain wordsIn this group of general practice patients with obesity, only 7 patients were prescribed liraglutide, because they also had diabetes.

    Peptide
    Liraglutide
    Outcome
    Not applicableNumber of patients prescribed liraglutide
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Whole body

    Measurements

    Patients prescribed liraglutide
    7 patients
    general practice cohort

    Source sentences

    Summary
    Liraglutide was prescribed only in 7 patients because of the concomitant presence of diabetes.
    1 context sentence
    Summary · context
    All patients registered in lists of 8 GPs with a recorded diagnosis of obesity or BMI values ≥ 30 kg/m2 in the period 2017-2018, were recruited.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.